A new structural class of proteasome inhibitors that prevent NF-κB activation

被引:37
|
作者
Lum, RT [1 ]
Kerwar, SS [1 ]
Meyer, SM [1 ]
Nelson, MG [1 ]
Schow, SR [1 ]
Shiffman, D [1 ]
Wick, MM [1 ]
Joly, A [1 ]
机构
[1] CV Therapeut Inc, Palo Alto, CA 94304 USA
关键词
proteasome; NF-kappa B; inflammation; proteolysis; proliferation;
D O I
10.1016/S0006-2952(97)00655-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The multicatalytic proteinase or proteasome is a highly conserved cellular structure that is responsible for the ATP-dependent proteolysis of many proteins involved in important regulatory cellular processes. We have identified a novel class of inhibitors of the chymotrypsin-like proteolytic activity of the 20S proteasome that exhibit IC50 values ranging from 0.1 to 0.5 mu g/mL (0.1 to 1 mu). In cell proliferation assays, these compounds inhibit growth with an IC50 ranging from 5 to 10 mu g/mL (10-20 mu M). A representative member of this class of inhibitors was tested in other biological assays. CVT-634 (5-methoxy-1-indanone-3-acetyl-leu-D-leu-1-indanylamide) prevented lipopolysaccharide (LPS), tumor necrosis factor (TNF)-, and phorbol ester-induced activation of nuclear factor kappa B (NF-kappa B) in vitro by preventing signal-induced degradation of I kappa B-alpha. In these studies, the I kappa B-alpha that accumulated was hyperphosphorylated, indicating that CVT-634 did not inhibit I kappa B-alpha kinase, the enzyme responsible for signal-induced phosphorylation of I kappa B-alpha. In vivo studies indicated that CVT-634 prevented LPS-induced TNF synthesis in a murine macrophage cell line. In addition, in mice pretreated with CVT-634 at 25 and 50 mg/kg and subsequently treated with LPS, serum TNF levels were significantly lower (225 +/- 59 and 83 +/- 41 pg/mL, respectively) than in those mice that were treated only with LPS (865 +/- 282 pg/mL). These studies suggest that specific inhibition of the chymotrypsin-like activity of the proteasome is sufficient to prevent signal-induced NF-kappa B activation and that the proteasome is a novel target for the identification of agents that may De useful in the treatment of diseases whose etiology is dependent upon the activation of NF-kappa B. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:1391 / 1397
页数:7
相关论文
共 50 条
  • [31] Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
    Kirsteen J Campbell
    John M O'Shea
    Neil D Perkins
    [J]. BMC Cancer, 6
  • [32] THE BIOLOGY OF A20-BINDING INHIBITORS OF NF-κB ACTIVATION (ABINS)
    Verstrepen, Lynn
    Carpentier, Isabelle
    Beyaert, Rudi
    [J]. MULTIPLE THERAPEUTIC TARGETS OF A20, 2014, 809 : 13 - 31
  • [33] Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C
    Matsumoto, N
    Ariga, A
    To-e, S
    Nakamura, H
    Agata, N
    Hirano, S
    Inoue, J
    Umezawa, K
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (09) : 865 - 869
  • [34] Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
    Campbell, Kirsteen J.
    O'Shea, John M.
    Perkins, Neil D.
    [J]. BMC CANCER, 2006, 6 (1)
  • [35] The effect of thioredoxin reductase inhibitors on NF-κB activation in HELA cells
    Heilman, J
    Watson, WH
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2005, 39 : S73 - S74
  • [36] NF-κB activation in sarcoidosis
    Drent, M
    van den Berg, R
    Haenen, GRMM
    van den Berg, H
    Wouters, EFM
    Bast, A
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2001, 18 (01) : 50 - 56
  • [37] NF-κB activation in melanoma
    Ueda, Y
    Richmond, A
    [J]. PIGMENT CELL RESEARCH, 2006, 19 (02): : 112 - 124
  • [38] Dissecting NF-κB activation
    Wilson, JDK
    [J]. NATURE IMMUNOLOGY, 2005, 6 (05) : 437 - 437
  • [39] Oncogenic Activation of NF-κB
    Staudt, Louis M.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (06): : a000109
  • [40] Direct Rel/NF-κB inhibitors: structural basis for mechanism of action
    Ouk, Samedy
    Liou, Mei-Ling
    Liou, Hsiou-Chi
    [J]. FUTURE MEDICINAL CHEMISTRY, 2009, 1 (09) : 1683 - 1707